FDA approves Sanofi's Menactra as meningococcal booster

The U.S. Centers for Disease Control and Prevention (CDC) currently recommends that adolescents receive one dose of meningococcal conjugate vaccine at age 11 or 12, followed by a booster vaccination at age 16. And as of this week, with an FDA approval for booster immunization, Sanofi's ($SNY) Menactra can now fulfill both of those guidelines. The new nod could boost sales of the French drugmaker's vaccine, a lift it could use after Menactra's top-line haul in 2013 sank to €424 million in a 21.5% slide. Release | More

Suggested Articles

The FDA is evaluating the possibility of prosecuting those involved in rogue herpes vaccine research led by a Southern Illinois University professor.

New legal complaints focus on eight Sanofi executives, most of them with local management titles, and 15 managers at distributor Zuellig Pharma.

Experts say technology is advancing to develop vaccines faster at a time of increasing emerging disease outbreaks.